Pharmaceutical industry
Advances in cancer therapies are giving new hope to patients and sparking optimism in the scientific community. With the development of molecular biology technologies, companies are now able to design and develop drugs that directly target cancer cells without causing side effects. This targeted approach has the potential to lead
Pharmaceutical industry
Matrix Pharmaceutical, Inc. announced the completion of enrollment in both United States and European clinical trials of IntraDose(TM) (cisplatin/epinephrine) Injectable Gel for the treatment of solid tumors. These trials are companion studies to Phase III registration-directed trials of IntraDose in patients with advanced head and neck cancer. The
Pharmaceutical industry
Imutec Pharma Inc., a Canadian pharmaceutical company, has announced positive results from its Phase I/II trial of Virulizin(R), an immunotherapy treatment for pancreatic cancer. The trial, conducted at the Rush Presbyterian St. Luke's Medical Center in Chicago, involved 26 patients with advanced-stage incurable pancreatic cancer. Of
Pharmaceutical industry
A groundbreaking approval by the U.S. Food and Drug Administration (FDA) has granted Eli Lilly and Company's anticancer agent Gemzar (gemcitabine HCl) a new indication for use in combination with cisplatin, a commonly used anticancer drug, for the first-line treatment of inoperable, locally advanced or metastatic non-small
Pharmaceutical industry
ILEX Oncology Inc. has announced a Phase III trial to evaluate the efficacy of its anticancer agent alpha-difluoromethylornithine (DFMO) in preventing non-melanoma skin cancer. The trial, led by Dr. Paul P. Carbone, will test DFMO against a placebo in a double-blind, controlled, randomized study of 340 patients with a history
Pharmaceutical industry
Techniclone Corporation, a developer of unique therapeutics for cancer treatment, announced the issuance of a U.S. patent for a portion of its Vascular Targeting Agent Technology on July 7. The patent, US 5,776,427, covers methods and compositions for targeting the vasculature of solid tumors. This breakthrough technology
Pharmaceutical industry
Perillyl alcohol, a novel monoterpene developed by Dr. Michael Gould and his team at the University of Wisconsin-Madison, has shown significant anti-tumor and preventative activity against a wide range of tumor types in pre-clinical studies. The compound has been licensed from the Wisconsin Alumni Research Foundation to Wisconsin Genetics, Inc.
Pharmaceutical industry
AVAX Technologies, a biopharmaceutical company, has initiated a pivotal trial for M-Vax, an experimental autologous vaccine designed to treat Stage 3 melanoma. The study aims to enroll 400 patients and compare the efficacy of M-Vax against high dose alpha interferon. The trial's primary endpoints are the rate of
Pharmaceutical industry
NaPro BioTherapeutics, a biopharmaceutical company based in Boulder, Colorado, has initiated patient treatment in U.S. clinical studies to explore the use of its patented formulation of paclitaxel in undisclosed cancer indications. The company's Q4D method of administration involves administering between 60 and 135 milligrams per meter of
Pharmaceutical industry
Immunomedics, a biopharmaceutical company, has announced the issuance of a patent (U.S. Patent 5,776,095) for a novel method of treating cancer using radiation or chemotherapy. This method involves protecting non-cancerous tissues and cells with targeted drugs that selectively bind to such tissues. The company's chairman,
Pharmaceutical industry
Researchers at Agouron Pharmaceuticals released encouraging results from phase I studies and a preclinical study of their oral anti-angiogenesis drug, AG3340. The data were presented at the 10th European Organization for Research and Treatment of Cancer (EORTC) meeting in Amsterdam, the Netherlands. AG3340 demonstrated promising anti-tumor activity, with over 25%
Pharmaceutical industry
ILEX Oncology, a San Antonio-based firm, aims to establish itself as the leading developer of anticancer drugs, as stated by its President and CEO, Richard Love, at the BIO '98 Investor & Partnering Conference. The company has built a strong portfolio of seven anticancer drugs in clinical development, with
